Reprogrammed pluripotent stem cells from somatic cells.
- Authors
- Kim, Jong Soo; Choi, Hyun Woo; Choi, Sol; Do, Jeong Tae
- Year
- 2011
- Journal
- International journal of stem cells
- PMID
- 24298328
- DOI
- 10.15283/ijsc.2011.4.1.1
- PMCID
- PMC3840974
Pluripotent stem cells, such as embryonic stem (ES) cells, can differentiate into all cell types. So, these cells can be a biological resource for regenerative medicine. However, ES cells known as standard pluripotent cells have problem to be used for cell therapy because of ethical issue of the origin and immune response on the graft. Hence, recently reprogrammed pluripotent cells have been suggested as an alternative source for regenerative medicine. Somatic cells can acquire the ES cell-like pluripotency by transferring somatic cell nuclei into oocytes, by cell fusion with pluripotent cells. Retroviral-mediated introduction of four factors, Oct4, Sox2, Klf4 and c-Myc can successfully reprogram somatic cells into ES cell-like pluripotent stem cells, known as induced pluripotent stem (iPS) cells. These cells closely resemble ES cells in gene expression pattern, cell biologic and phenotypic characteristics. However, to reach the eventual goal of clinical application, it is necessary to overcome the major drawbacks such as low reprogramming efficiency and genomic alterations due to viral integration. In this review, we discuss the current reprogramming techniques and mechanisms of nuclear reprogramming induced by transcription factor transduction.
No figures extracted from this document.
No chunks β full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
No citations found.
In this knowledge base
| Title | Year | PMID |
|---|---|---|
| Using human stem cells as a model system to understand the neural mechanisms of alcohol use disorders: Current status and outlook. | 2019 | 30087005 |
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Advances in Genetic Reprogramming: Prospects from Developmental Biology to Regenerative Medicine. | Dhanjal DS et al. | β | 2024 | β |
| Inducing Pluripotency in Somatic Cells: Historical Perspective and Recent Advances. | Park J et al. | β | 2024 | β |
| Stem cell modeling of nervous system tumors. | Furnari FB et al. | β | 2024 | β |
| Transcriptional Factors Mediated Reprogramming to Pluripotency. | Fatima N et al. | β | 2024 | β |
| Unlocking the therapeutic potential: odyssey of induced pluripotent stem cells in precision cell therapies. | Mohite P et al. | β | 2024 | β |
| Mitochondrial regulation in human pluripotent stem cells during reprogramming and Ξ² cell differentiation. | Jasra IT et al. | β | 2023 | β |
| The Promises and Pitfalls of CRISPR-Mediated Base Editing in Stem Cells. | Wong PK et al. | β | 2023 | β |
| The revolution of PDMS microfluidics in cellular biology. | Banik S et al. | β | 2023 | β |
| Applications of Tissue Nano-Transfection Technology (TNT): a systematic review | Hagar E et al. | β | 2022 | β |
| Chemically modified mRNA beyond COVID-19: Potential preventive and therapeutic applications for targeting chronic diseases. | Elkhalifa D et al. | β | 2022 | β |
| Autophagy and senescence: Insights from normal and cancer stem cells. | Talukdar S et al. | β | 2021 | β |
| Bioengineered optogenetic model of human neuromuscular junction. | Vila OF et al. | β | 2021 | β |
| Dynamic mechanical loading and growth factors influence chondrogenesis of induced pluripotent mesenchymal progenitor cells in a cartilage-mimetic hydrogel. | Aisenbrey EA et al. | β | 2019 | β |
| Genetic circuits to engineer tissues with alternative functions. | Healy CP et al. | β | 2019 | β |
| Nuclear transplantation between allogeneic cells through topological reconnection of plasma membrane in a microfluidic system. | Okanojo M et al. | β | 2019 | β |
| Synthetic biology for improving cell fate decisions and tissue engineering outcomes. | Vogel AM et al. | β | 2019 | β |
| Using human stem cells as a model system to understand the neural mechanisms of alcohol use disorders: Current status and outlook. | Scarnati MS et al. | β | 2019 | β |
| A Pathway to Personalizing Therapy for Metastases Using Liver-on-a-Chip Platforms. | Khazali AS et al. | β | 2017 | β |
| Folic Acid Supports Pluripotency and Reprogramming by Regulating LIF/STAT3 and MAPK/ERK Signaling. | Wei T et al. | β | 2017 | β |
| Aging of Stem and Progenitor Cells: Mechanisms, Impact on Therapeutic Potential, and Rejuvenation. | Nurkovic J et al. | β | 2016 | β |